Getinge and 908 Devices Partner to Enhance Bioreactor Capabilities for Continuous Monitoring of Key Cell Culture Parameters
908 Devices (Nasdaq: MASS) and Getinge have announced a partnership to integrate their technologies for enhanced bioreactor monitoring. The collaboration combines Getinge's bioreactors with 908 Devices' MAVEN system for automated control of glucose and lactate levels in cell cultures.
The integrated solution enables continuous, real-time analysis without manual sampling, allowing biopharma scientists to maintain optimal nutrient concentrations. MAVEN can monitor up to two bioreactors simultaneously, with data being managed through Getinge's advanced controllers. The system will be compatible with Getinge's Livit Flex controller and connected through Livit Links sensor ports.
908 Devices (Nasdaq: MASS) e Getinge hanno annunciato una partnership per integrare le loro tecnologie al fine di migliorare il monitoraggio dei bioreattori. La collaborazione unisce i bioreattori di Getinge con il sistema MAVEN di 908 Devices per il controllo automatizzato dei livelli di glucosio e lattato nelle colture cellulari.
La soluzione integrata consente un'analisi continua e in tempo reale senza campionamento manuale, permettendo agli scienziati biopharma di mantenere concentrazioni ottimali di nutrienti. MAVEN può monitorare simultaneamente fino a due bioreattori, con i dati gestiti attraverso i controller avanzati di Getinge. Il sistema sarà compatibile con il controller Livit Flex di Getinge e collegato tramite le porte sensore Livit Links.
908 Devices (Nasdaq: MASS) y Getinge han anunciado una asociación para integrar sus tecnologías y mejorar el monitoreo de biorreactores. La colaboración combina los biorreactores de Getinge con el sistema MAVEN de 908 Devices para el control automatizado de los niveles de glucosa y lactato en cultivos celulares.
La solución integrada permite un análisis continuo y en tiempo real sin muestreo manual, lo que permite a los científicos biopharma mantener concentraciones óptimas de nutrientes. MAVEN puede monitorear hasta dos biorreactores simultáneamente, gestionando los datos a través de los controladores avanzados de Getinge. El sistema será compatible con el controlador Livit Flex de Getinge y se conectará a través de los puertos de sensores Livit Links.
908 디바이스 (Nasdaq: MASS)와 게팅에가 생물 반응기 모니터링을 개선하기 위해 기술 통합을 발표했습니다. 이 협력은 게팅의 생물 반응기와 908 디바이스의 MAVEN 시스템을 결합하여 세포 배양에서 포도당과 젖산 수준을 자동으로 제어합니다.
통합 솔루션은 수동 샘플링 없이 실시간으로 지속적인 분석을 가능하게 하고, 생명과학 연구원들이 최적의 영양소 농도를 유지할 수 있게 합니다. MAVEN은 최대 두 개의 생물 반응기를 동시에 모니터링할 수 있으며, 데이터는 게팅의 고급 컨트롤러를 통해 관리됩니다. 이 시스템은 게팅의 Livit Flex 컨트롤러와 호환되며, Livit Links 센서 포트를 통해 연결됩니다.
908 Devices (Nasdaq: MASS) et Getinge ont annoncé un partenariat pour intégrer leurs technologies pour améliorer la surveillance des bioréacteurs. La collaboration associe les bioréacteurs de Getinge au système MAVEN de 908 Devices pour le contrôle automatisé des niveaux de glucose et de lactate dans les cultures cellulaires.
La solution intégrée permet une analyse continue en temps réel sans échantillonnage manuel, permettant ainsi aux scientifiques biopharmaceutiques de maintenir des concentrations optimales de nutriments. MAVEN peut surveiller jusqu'à deux bioréacteurs simultanément, les données étant gérées via les contrôleurs avancés de Getinge. Le système sera compatible avec le contrôleur Livit Flex de Getinge et sera connecté via les ports de capteur Livit Links.
908 Devices (Nasdaq: MASS) und Getinge haben eine Partnerschaft angekündigt, um ihre Technologien für eine verbesserte Bioreaktorüberwachung zu integrieren. Die Zusammenarbeit kombiniert die Bioreaktoren von Getinge mit dem MAVEN-System von 908 Devices zur automatisierten Kontrolle der Glukose- und Laktatwerte in Zellkulturen.
Die integrierte Lösung ermöglicht eine kontinuierliche Echtzeitanalyse ohne manuelles Sampling, wodurch Biopharma-Wissenschaftler optimale Nährstoffkonzentrationen aufrechterhalten können. MAVEN kann bis zu zwei Bioreaktoren gleichzeitig überwachen, wobei die Daten über Getinges fortschrittliche Controller verwaltet werden. Das System wird mit Getinges Livit Flex-Controller kompatibel sein und über die Livit Links-Sensoranschlüsse verbunden werden.
- Partnership enables automated, real-time monitoring of critical cell culture parameters
- Technology integration allows continuous analysis without sample loss
- System can monitor multiple bioreactors simultaneously
- Solution aims to improve productivity and reduce time to market
- None.
Insights
The partnership between Getinge and 908 Devices represents a strategic advancement in bioprocessing technology, though its immediate financial impact may be The integration of MAVEN with Getinge's bioreactors addresses a critical need in biopharmaceutical development by automating glucose and lactate monitoring - traditionally a manual, time-consuming process.
The real value proposition lies in the potential for accelerated drug development timelines and improved process efficiency. By enabling continuous, real-time monitoring without sample loss, this solution could reduce development costs and time-to-market for biopharmaceutical companies. For 908 Devices, with a relatively small market cap of
However, the revenue impact will likely materialize gradually as adoption among biopharmaceutical companies typically follows a conservative pathway, requiring extensive validation before implementation. The partnership primarily strengthens 908 Devices' competitive position in the bioprocessing tools market rather than promising immediate significant revenue growth.
From a technical perspective, the MAVEN integration offers compelling advantages over traditional sampling methods. The ability to maintain optimal nutrient levels without depleting reactor volume is particularly valuable for small-scale development work where volume loss can significantly impact results. The dual-reactor monitoring capability enhances laboratory efficiency, while the integration with Getinge's Livit Flex controller provides sophisticated control capabilities that could improve process reproducibility.
In simpler terms, imagine trying to keep the perfect amount of sugar in your coffee while drinking it - traditional methods require you to keep tasting it (removing liquid each time), while this system constantly measures without taking any coffee out. This means better results and less waste of valuable materials.
The system's ability to monitor very low concentrations is especially relevant for high-value protein production processes where precise control can significantly impact product quality and yield. However, market penetration will depend heavily on validation studies demonstrating improved outcomes compared to established methods.
In the field of bioprocessing, the continuous monitoring of glucose and lactate levels is crucial for optimizing cell culture conditions and thereby the research and development of biopharmaceutical products. Accurate measurement of these parameters allows for better control of the bioreactor environment, leading to improved productivity and reduced time to market.
908 Devices’ MAVEN provides highly precise, on-line monitoring and control of glucose and lactate without any loss of bioreactor volume, enabling biopharma scientists to maintain optimal nutrient and metabolite concentrations, even at very low levels. Data from MAVEN is collected and supervised through Getinge’s advanced controllers. It can set up control loops, recipe functionality and advanced control, and has the capacity to measure from up to two bioreactors simultaneously.
“We are thrilled to collaborate with 908 Devices on this joint solution to make our customers’ life in the lab easier. This means continuous visibility into concentration changes, continuous control of glucose levels, and the ability to adjust control strategies based on real-time measurements, such as starting feeding or stopping cultivation. This enables our customers to increase productivity and go faster to market,” explains Timo Keijzer, Director Product Marketing at Getinge.
Timo’s emphasis on seamless lab workflows is echoed by Christopher D. Brown, Chief Product Officer and Co-founder at 908 Devices, who adds: “We’re excited to partner with Getinge as we share a mutual passion to enable our biopharma customers with modern bioprocess automation tools for control of critical process parameters, thereby increasing their process understanding and accelerating development workflows. In addition, implementing robust control strategies in development optimizes product performance and facilitates a scalable process.”
The MAVEN device will be compatible with Getinge’s Livit Flex controller and connected through Livit Links sensor ports. Find out more about Getinge’s bioreactors.
About Getinge
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.
About 908 Devices
908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in bioprocessing, pharma/biopharma, forensics, life sciences research and adjacent markets. The Company is headquartered in the heart of
Forward Looking Statements for 908 Devices
This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241219224577/en/
Media Contact for 908 Devices
Barbara Russo
brusso@908devices.com
Investor Contact for 908 Devices
Carrie Mendivil
IR@908devices.com
Source: 908 Devices Inc.
FAQ
What is the purpose of the partnership between 908 Devices (MASS) and Getinge?
How many bioreactors can the MAVEN system monitor simultaneously?
What are the key benefits of the MASS-Getinge integrated bioreactor solution?
Which Getinge controllers is the MAVEN system compatible with?
